Appln. No. 09/987,701 Amd. dated December 1, 2004 Reply to Office Action of September 8, 2004

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1(Currently amended). [[A]] An isolated polypeptide which interacts with, and has the activity of modulating the stability of[[,]] transcriptional regulatory complexes that regulate nuclear hormone receptor activity, comprising an amino acid sequence of SEQ ID NO:2, or a fragment or variant thereof, wherein said fragment retains the activity of the polypeptide and said variant comprises an amino acid sequence having at least [[85%]] 90% sequence identity with SEQ ID NO:2 and has the activity of modulating the stability of transcriptional regulatory complexes that regulate nuclear hormone receptor activity.

2 (Currently amended). The <u>isolated</u> polypeptide of claim 1 which comprises the amino acid sequence of SEQ ID NO:2.

Claims 3 and 4 (Cancelled)

5 (Currently amended). The <u>isolated</u> variant polypeptide of claim 4, which comprises the amino acid sequence of SEQ ID NO:4.

Appln. No. 09/987,701 Amd. dated December 1, 2004 Reply to Office Action of September 8, 2004

6(Currently amended). The <u>isolated</u> variant polypeptide of claim 3, wherein said sequence identity is at least 95%.

7(Currently amended). The <u>isolated</u> variant polypeptide of claim 6, which comprises the amino acid sequence of SEQ ID NO:12.

8 (Currently amended). A molecule which includes the antigen-binding portion of an antibody specific for the <u>isolated</u> polypeptide of claim 1.

9(Original). The molecule of claim 8, which is selected from the group consisting of monoclonal antibody, humanized antibody and single-chain antibody.

Claims 10-18 (Cancelled).